With their study, Laporte and colleagues address an important question with regard to the prevention of catheter-related thrombosis in patients with cancer.1 Until recently, only 2 prospective randomized controlled trials were available on this subject, and although both found a reduction in catheter-related thrombosis with the use of anticoagulants, no definite overall conclusions could be drawn since they studied different types of thromboprophylaxis (low-dose warfarin and low-molecular-weight heparin).2,3 Therefore, there was a need for a study that compared these 2 types of anticoagulants head-to-head. And this is exactly what Laporte and colleagues did.
Clara P. W. Klerk, Harry R. Büller. Thrombosis Prophylaxis in Cancer Patients With a Central Venous Catheter—Reply. Arch Intern Med. 2004;164(4):459–460. doi:10.1001/archinte.164.4.459-b